Myricetin induces apoptosis and enhances chemosensitivity in ovarian cancer cells

Oncology Letters

Volumn 13, Issue 6, 2017, Pages 4974-4978

  Zheng, Ai Wen ^a   Chen, Ya Qing ^a   Zhao, Ling Qin ^a   Feng, Jian Guo ^b  

^a Department of Gynecologic Oncology ^*  (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Apoptosis; Chemoresistance; Myricetin; Ovarian cancer

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; MYRICETIN; PACLITAXEL; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER MORTALITY; CELL MIGRATION; CELL VIABILITY ASSAY; CHEMOSENSITIVITY; CYTOTOXICITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; OVARIAN CANCER CELL LINE; OVARY CANCER; OVARY TUMOR; PHENOTYPE; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 85019765013     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2017.6031     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, Giglio S, Sonego M, Cirombella R, Onesti EC, Pellegrini P, et al: A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci USA 110: 9845-9850, 2013.
3. Jayson GC, Kohn EC, Kitchener HC and Ledermann JA: Ovarian cancer. Lancet 384: 1376-1388, 2014.
4. Nam MS, Jung DB, Seo KH, Kim BI, Kim JH, Kim JH, Kim B, Baek NI and Kim SH: Apoptotic effect of sanggenol L via caspase activation and inhibition of NF-kB signaling in ovarian cancer cells. Phytother Res 30: 90-96, 2016.
5. Ivanov S, Ivanov S and Khadzhiolov N: Ovarian tumours-accu-racy of frozen section diagnosis. Akush Ginekol (Sofiia) 44: 11-13, 2005 (In Bulgarian).
6. Saika K and Sobue T: Cancer statistics in the world. Gan To Kagaku Ryoho 40: 2475-2480, 2013 (In Japanese).
7. Edwards SJ, Barton S, Thurgar E and Trevor N: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: A systematic review and economic evaluation. Health Technol Assess 19: 1-480, 2015.
8. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, et al: Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A Phase III Trial of the gynecologic cancer intergroup. J Clin Oncol 27: 1419-1425, 2009.
9. Sak K: Site-specific anticancer effects of dietary flavonoid quer-cetin. Nutr Cancer 66: 177-193, 2014.
10. Sak K: Cytotoxicity of dietary flavonoids on different human cancer types. Pharmacogn Rev 8: 122-146, 2014.
11. Gupta S, Afaq F and Mukhtar H: Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem Biophys Res Commun 287: 914-920, 2001.
12. Devi KP, Rajavel T, Habtemariam S, Nabavi SF and Nabavi SM: Molecular mechanisms underlying anticancer effects of myricetin. Life Sci 142: 19-25, 2015.
13. Harnly JM, Doherty RF, Beecher GR, Holden JM, Haytowitz DB, Bhagwat S and Gebhardt S: Flavonoid content of U.S. fruits, vegetables, and nuts. J Agric Food Chem 54: 9966-9977, 2006.
14. Ong CK, Nee S, Rambaut A, Bernard HU and Harvey PH: Elucidating the population histories and transmission dynamics of papillomaviruses using phylogenetic trees. J Mol Evol 44: 199-206, 1997.
15. Boam T: Anti-androgenic effects of flavonols in prostate cancer. Ecancermedicalscience 9: 585, 2015.
16. Feng J, Chen X, Wang Y, Du Y, Sun Q, Zang W and Zhao G: Myricetin inhibits proliferation and induces apoptosis and cell cycle arrest in gastric cancer cells. Mol Cell Biochem 408: 163-170, 2015.
17. Iyer SC, Gopal A and Halagowder D: Myricetin induces apoptosis by inhibiting P21 activated kinase 1 (PAK1) signaling cascade in hepatocellular carcinoma. Mol Cell Biochem 407: 223-237, 2015.
18. Maggioni D, Nicolini G, Rigolio R, Biffi L, Pignataro L, Gaini R and Garavello W: Myricetin and naringenin inhibit human squamous cell carcinoma proliferation and migration in vitro. Nutr Cancer 66: 1257-1267, 2014.
19. Huang H, Chen AY, Ye X, Li B, Rojanasakul Y, Rankin GO and Chen YC: Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway. Int J Oncol 47: 1494-1502, 2015.
20. Yi JL, Shi S, Shen YL, Wang L, Chen HY, Zhu J and Ding Y: Myricetin and methyl eugenol combination enhances the anticancer activity, cell cycle arrest and apoptosis induction of cis-platin against HeLa cervical cancer cell lines. Int J Clin Exp Pathol 8: 1116-1127, 2015.
21. Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I, Brown EJ, Capobianco AJ, Herlyn M and Liu ZJ: Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest 115: 3166-3176, 2005.
22. Tavassoli FA and Norris HJ: Sertoli tumors of the ovary. A clinicopathologic study of 28 cases with ultrastructural observations. Cancer 46: 2281-2297, 1980.
23. Burton ER, Brady M, Homesley HD, Rose PG, Nakamura T, Kesterson JP, Rotmensch J, Tate Thigpen J and Van Le L: A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG oncology/gynecologic oncology group study. Gynecol Oncol 140: 48-52, 2016.
24. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
25. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234, 2006.
26. Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S and Fojo T: Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the national cancer institute anticancer drug screen. J Clin Invest 95: 2205-2214, 1995.
27. Chen H, Hao J, Wang L and Li Y: Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101: 432-440, 2009.
28. Wang B, Li S, Meng X, Shang H and Guan Y: Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells. Tumour Biol 36: 6433-6443, 2015.
29. Zhang H, Wang J, Cai K, Jiang L, Zhou D, Yang C, Chen J, Chen D and Dou J: Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells. J Cancer Res Ther 8: 226-231, 2012.